All In Biotech

Drug Trial Radar · NCT01331837

A Study of Tocilizumab in Comparison to Etanercept in Participants With Rheumatoid Arthritis and Cardiovascular Disease Risk Factors

A Clinical Outcomes Study to Evaluate the Effects of IL-6 Receptor Blockade With Tocilizumab (TCZ) in Comparison With Etanercept (ETA) on the Rate of Cardiovascular Events in Patients With Moderate to Severe Rheumatoid Arthritis (RA)

Last checked: Nov 20, 2026Latest source record: Jul 13, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 3,080 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

3,080

Actual

Start

Aug 2, 2011

Primary completion

Mar 25, 2016

Study completion Mar 25, 2016

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Apr 8, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This randomized, open-label, parallel-group, multicenter study will evaluate the rate of cardiovascular events with tocilizumab in comparison to etanercept in participants with rheumatoid arthritis (RA). Participants will be randomized to receive intravenous (IV) 8 milligrams per kilogram (mg/kg) tocilizumab every 4 weeks or subcutaneous 50 milligrams (mg) etanercept weekly, with or without non-biologic disease-modifying anti-rheumatic drug (DMARD).

Conditions

  • Rheumatoid Arthritis

Interventions

  • EtanerceptDrug

    Participants will receive 50 mg etanercept subcutaneously weekly until switch to another RA therapy or up to 4.9 years.

  • TocilizumabDrug

    Participants will receive 8 mg/kg tocilizumab IV every 4 weeks until switch to another RA therapy or up to 4.9 years.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to First Cardiovascular (CV) Events Adjudication Committee (EAC) (CV-EAC) Adjudicated EventTime frame: From baseline up to 4.9 years
  2. Percentage of Patients Reporting a Cardiovascular (CV) Events Adjudication Committee (EAC) (CV-EAC) Adjudicated EventTime frame: From baseline up to 4.9 years
  3. Time to First CV-EAC Adjudicated Event - Sensitivity AnalysisTime frame: From Baseline up to 4.9 years
  4. Percentage of Patients With a CV-EAC Adjudicated Event - Sensitivity AnalysisTime frame: From Baseline up to 4.9 years
  5. Time to First CV-EAC Adjudicated Event Excluding Undetermined Cause of Death - Sensitivity AnalysisTime frame: From baseline up to 4.9 years
  6. Percentage of Patients With a CV-EAC Adjudicated Event Excluding Undetermined Cause of Death - Sensitivity AnalysisTime frame: From baseline up to 4.9 years
  7. Time to First CV-EAC Adjudicated Event Before Last Direct Contact DateTime frame: From Baseline up to 4.9 years
  8. Percentage of Participants With a CV-EAC Adjudicated Event Before Last Direct Contact DateTime frame: From Baseline up to 4.9 years

Locations

428 sites in 31 countries. Site status is shown where the registry gives one.

  • Uni Of Alabama,Birmingham; Medicine - Rheumatology

    Birmingham, Alabama

  • Rheumatology Associates of North Alabama

    Huntsville, Alabama

  • Clinical and Translational Research Center of Alabama, PC

    Tuscaloosa, Alabama

  • Arizona Arthritis & Rheumatology Associates, P.C.

    Glendale, Arizona

  • Arizona Arthritis & Rheumatology Research, Pllc

    Paradise Valley, Arizona

  • Sun Valley Arthritis Center

    Peoria, Arizona

  • Valley Arthritis Care

    Phoenix, Arizona

  • Advanced Arthritis Care & Research

    Scottsdale, Arizona

  • Camp Lowell Medical Specialists

    Tucson, Arizona

  • The University of Arizona

    Tucson, Arizona

  • NEA Baptist Clinic

    Jonesboro, Arkansas

  • OrthoArkansas; Orthopedics & Sports Medicine

    Little Rock, Arkansas

  • Samy Metyas, MD, Inc

    Covina, California

  • Talbert Medical Group

    Huntington Beach, California

  • Allergy & Rheumatology Medical Clinic, Inc

    La Jolla, California

  • Valerius Medical Group

    Los Alamitos, California

  • Clinical Interventions Research Institute

    Mission Viejo, California

  • Dr. Brigid Freyne, MD

    Murrieta, California

  • Sharp Rees-Stealy Medical Group

    Poway, California

  • San Diego Arthritis Med Clnc

    San Diego, California

  • Purushotham & Akther Kotha Inc

    San Diego, California

  • C Michael Neuwelt MD Inc

    San Leandro, California

  • Pacific Arthritis Ctr Med Grp

    Santa Maria, California

  • Orrin M. Troum, Md

    Santa Monica, California

  • Harbor UCLA Medical Center

    Torrance, California

  • Inland Rheumatology; Clinical Trials, Inc.

    Upland, California

  • Medvin Clinical Research

    Whittier, California

  • Arthritis Assoc & Osteoporosis; Ctr of Colorado Springs

    Colorado Springs, Colorado

  • Joao Nascimento

    Bridgeport, Connecticut

  • University of Connecticut Health Center

    Farmington, Connecticut

  • Arthritis & Osteoporosis Center Pc

    Hamden, Connecticut

  • ZASA Clinical Research

    Boynton Beach, Florida

  • DC Health Clinic

    Coral Gables, Florida

  • Tsai, Yong

    Daytona Beach, Florida

  • Jacksonville Center For Clinical Research

    Jacksonville, Florida

  • Pharmax Research Clinic Inc.

    Miami, Florida

  • Arthritis/Osteoporosis Treatment Center

    Orange Park, Florida

  • Arthritis Rsrch of Florida, Inc.

    Palm Harbor, Florida

  • Baptist Hospital Clinical Research

    Pensacola, Florida

  • Lovelace Scientific Resources

    Sarasota, Florida

Showing 40 of 428 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.